Meridigen New Stem Cell Drug Might Help Fight the New Coronavirus

New Hope for Novel Coronavirus! Meridigen Develops “Umbilical Cord Mesenchymal Stem Cell Therapy”

Meridigen applied a self-developed human umbilical mesenchymal stem cell drug (UMC119-06) for the treatment of Acute Respiratory Distress Syndrome (ARDS) in Phase I clinical trial. Currently approved by the US Food and Drug Administration (FDA) on January

Meridigen initiates Phase 1 clinical trial for new cell therapy.

Rising Beyond the Bar of Special Regulations, Meridigen Launch its Phase 1 Clinical Trial